SHH:603811
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. · SHH · Healthcare · CNY · FY for 2025
Figures on this page computed 2026-11-08 13:26 UTC
Last close
n/aCNY
Market data
11.0xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
24.0%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
28.9%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
3.9%Dividend yield
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
Growth is the furthest below its sector's middle: 0.33 against 0.47 on the market's range.
Follow one yuan
lens 1 of 9The five stops
5 of 5 read- After what it costs to make567,013,59369.8%
- After running the business224,601,46827.7%
- After interest and tax195,116,71624.0%
- After what it must reinvest234,987,95828.9%
- Kept after the dividend151,510,75518.7%
Of every unit of sales, 0.19 is still there after the dividend.
Of every unit of sales, 0.19 is still there after the dividend.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2025
Sales812,349,118
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
After what it costs to make567,013,593
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
After running the business224,601,468
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
After interest and tax195,116,716
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
After what it must reinvest234,987,958
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Kept after the dividend151,510,755
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY